Clinical trial
A Prospective Randomized Phase 2 Study of Dose and Volume De-escalation Radiotherapy With Sentinel Lymph Nodes Mapping for Contralateral Irradiation in Unilaterally Node Positive Head and Neck Squamous Cell Carcinomas (SEMIRAHN)
NCT04688528 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Randomized Phase 2 Study of Dose and Volume De-escalation Radiotherapy With Sentinel Lymph Nodes Mapping for Contralateral Irradiation in Unilaterally Node Positive Head and Neck Squamous Cell Carcinomas (SEMIRAHN)
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- June 10, 2021
- Completion date
- January 31, 2027
- Enrollment
- 147 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.